Trimetazidine structure
|
Common Name | Trimetazidine | ||
---|---|---|---|---|
CAS Number | 5011-34-7 | Molecular Weight | 274.385 | |
Density | 1.1±0.1 g/cm3 | Boiling Point | 364.0±37.0 °C at 760 mmHg | |
Molecular Formula | C14H22N2O3 | Melting Point | 200 - 205ºC | |
MSDS | N/A | Flash Point | 174.0±26.5 °C |
Use of TrimetazidineTrimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective drug, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4]. |
Name | 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine |
---|---|
Synonym | More Synonyms |
Description | Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective drug, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4]. |
---|---|
Related Catalog | |
Target |
IC50: 75 nM (long chain 3-ketoyl coenzyme A thiolase)[2] β-oxidation[2] Autophagy[3] 3-hydroxyacyl-CoA dehydrogenase (HADHA)[4] |
In Vitro | Trimetazidine (1-100 μM; 24 hours; HUVECs) could enhance the viability of the injured HUVECs induced by oxidation in a certain dose-dependent manner[1]. Cell Viability Assay[1] Cell Line: Human umbilical vein endothelial cells (HUVECs) Concentration: 1 μM,10 μM,100 μM Incubation Time: 24 hours Result: Enhanced the viability of the injured HUVECs induced by oxidation. |
In Vivo | Trimetazidine (5-20 mg/kg; oral administration; 1 hour; Swiss albino male mice) in 10 and 20mg/kg doses significantly raises the seizure-threshold current in the ICES test in the mice[5]. Animal Model: Swiss albino male mice (24-35 g)[4] Dosage: 5 mg/kg, 10 mg/kg and 20 mg/kg; 10 mL/kg body weight Administration: Oral administration ; 1 hour Result: In 10 and 20mg/kg doses significantly raised the seizure-threshold current in the ICES test. |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 364.0±37.0 °C at 760 mmHg |
Melting Point | 200 - 205ºC |
Molecular Formula | C14H22N2O3 |
Molecular Weight | 274.385 |
Flash Point | 174.0±26.5 °C |
Exact Mass | 274.213257 |
PSA | 42.96000 |
LogP | 0.80 |
Vapour Pressure | 0.0±0.8 mmHg at 25°C |
Index of Refraction | 1.524 |
Hazard Codes | Xi |
---|---|
HS Code | 2933599090 |
~% Trimetazidine CAS#:5011-34-7 |
Literature: Ferte, Jacques; Kuehnel, Jean-Marc; Chapuis, Genevieve; Rolland, Yves; Lewin, Guy; Schwaller, Marc A. Journal of Medicinal Chemistry, 1999 , vol. 42, # 3 p. 478 - 489 |
~% Trimetazidine CAS#:5011-34-7 |
Literature: Ferte, Jacques; Kuehnel, Jean-Marc; Chapuis, Genevieve; Rolland, Yves; Lewin, Guy; Schwaller, Marc A. Journal of Medicinal Chemistry, 1999 , vol. 42, # 3 p. 478 - 489 |
Precursor 2 | |
---|---|
DownStream 0 |
HS Code | 2933599090 |
---|---|
Summary | 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Piperazine-2,2,3,3,5,5,6,6-d, 1-[(2,3,4-trimethoxyphenyl)methyl]- |
Trimetazidine HCl |
EINECS 225-690-2 |
MFCD00868263 |
Trimetazidine |
1-(2,3,4-Trimethoxybenzyl)(2,2,3,3,5,5,6,6-H)piperazine |